Novo Nordisk Pharma Co., Ltd. (Japan) announced an adaptation to the existing approval for its long-acting human growth hormone analog formulation “Sogrua” (generic name: Somapsitan (genetically modified)). The… read more.
Arrowhead Pharmaceuticals, Inc. announced that the European Commission (EC) has formally granted marketing authorization for Redemplo (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet… read more.
DNA testing kits are often gifted for Father’s Day, Christmas and special occasions. The idea of learning more about yourself and unearthing some long-forgotten family history is certainly… read more.
UCB announced that the European Commission (EC) has granted marketing authorization under exceptional circumstances for Kygevvi (doxecitine and doxribtimine) for the treatment of paediatric and adult patients with… read more.
In the coming weeks, the Human Genome and Stem Cell Research Center (HUG-CELL) will begin recruiting participants for the “Our Genes” project. The initiative aims to identify couples at an… read more.
Oral corticosteroids (OCSs) are widely used and effective in the treatment of chronic inflammatory conditions such as arthritis, asthma, and autoimmune diseases. They work by reducing inflammation, relieving… read more.
Krystal Biotech announced that, on May 15, 2026, the United Kingdom MHRA granted marketing authorization to Vyjuvek (beremagene geperpavec-svdt) for the treatment of wounds in patients with dystrophic epidermolysis… read more.
Denali Therapeutics Inc. announced the FDA has granted accelerated approval for Avlayah (tividenofusp alfa-eknm), the first FDA-approved biologic specifically designed to cross the blood-brain barrier and reach the… read more.
A collaboration between Karolinska Institutet, Karolinska University Hospital, and SciLifeLab has integrated whole genome sequencing into routine diagnostic investigations for rare diseases at Karolinska University Hospital. To date,… read more.
Ascendis Pharma announced that Yuviwel (navepegritide; developed as TransCon CNP) was granted orphan drug exclusivity by the FDA and that Yuviwel is now commercially available in the United… read more.
PTC Therapeutics Inc. announced that it has withdrawn the New Drug Application (NDA) resubmission for Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (DMD) following… read more.
Zevra Therapeutics announced the presentation of four posters highlighting positive new data on Miplyffa (arimoclomol) for the treatment of Niemann-Pick Disease Type C (NPC) at the 22nd Annual… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
